Strontium-89: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 26: | Line 26: | ||
{{Medicine-stub}} | {{Medicine-stub}} | ||
{{Chemistry-stub}} | {{Chemistry-stub}} | ||
<gallery> | |||
File:Metastron_(Strontium-89),_GE_Healthcare.jpg | |||
</gallery> | |||
Latest revision as of 22:04, 16 February 2025
Strontium-89 is a radioactive isotope of strontium, a chemical element with the symbol Sr and atomic number 38. It is used in the treatment of bone cancer and bone metastases, particularly in patients with prostate cancer.
Properties[edit]
Strontium-89 has a half-life of approximately 50.5 days. It decays by beta decay into yttrium-89, releasing beta particles that can kill cancer cells. The isotope is chemically similar to calcium, which allows it to be incorporated into the bone where it can target cancer cells.
Medical Use[edit]
Strontium-89 is used in the form of Strontium Chloride Sr-89 Injection, a radiopharmaceutical agent used for the relief of cancer-induced bone pain. It is administered intravenously and is absorbed by the bone tissue, where it delivers a high dose of radiation to the cancer cells.
Production[edit]
Strontium-89 is produced in a nuclear reactor by the neutron bombardment of strontium-88. The resulting strontium-89 is then purified and formulated into a sterile solution for medical use.
Safety[edit]
As a radioactive substance, strontium-89 must be handled with care to prevent unnecessary exposure. It is important to follow all safety guidelines when handling and administering this isotope.
See Also[edit]

